2653 monitored
← Actor desksRead-only · existing recordsClassic graph view ↗

Sentinels / Actor desk

Liza Helies

person · Registry status: unverified

2b5a5cef-ff24-5a1a-8b4f-f1d5693f95f1

Evidence, not intent.

Public-source event mentions and stored signals. Adjacency does not establish causation, coordination, or an actor's position.

No claim of complete coverage or live monitoring.

Observation window

UTC dates, inclusive · maximum 90 days. Applies to events and anomalies only.

Recent observations / timeline

The source record

19 distinct events shown, newest first. Headlines may be generated summaries; inspect the source before repeating a claim.

  1. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · TAX_DISEASE_GASTROINTESTINAL

    Open source ↗
  2. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · AFFECT

    Open source ↗
  3. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · TAX_FNCACT_CHIEF

    Open source ↗
  4. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · TAX_DISEASE_HEPATOCELLULAR_CARCINOMA

    Open source ↗
  5. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_2024_ANTI_CORRUPTION_AUTHORITIES

    Open source ↗
  6. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_1160_SHOCKS_AND_VULNERABILITY

    Open source ↗
  7. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · SCIENCE

    Open source ↗
  8. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_845_LEGAL_AND_REGULATORY_FRAMEWORK

    Open source ↗
  9. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · EPU_POLICY_REFORM

    Open source ↗
  10. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_1614_NUTRITIONAL_PROGRAMS

    Open source ↗
  11. BeOne Medicines Ltd.: BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_756_VULNERABLE_GROUPS

    Open source ↗
  12. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · WB_346_COMPETITIVE_INDUSTRIES

    Open source ↗
  13. BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Recorded role: co mention · TAX_DISEASE_THROMBOCYTOPENIA

    Open source ↗
  14. BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

    Recorded role: co mention · WB_346_COMPETITIVE_INDUSTRIES

    Open source ↗
  15. BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

    Recorded role: co mention · WB_969_CAPITAL_MARKETS_LAW_AND_REGULATION

    Open source ↗
  16. BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

    Recorded role: co mention · LEGISLATION

    Open source ↗
  17. BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

    Recorded role: co mention · TAX_WORLDMAMMALS_HUMAN

    Open source ↗
  18. BeOne Medicines Successfully Completes Negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for TEVIMBRA® in first-line Recurrent or Metastatic Nasopharyngeal Carcinoma

    Recorded role: co mention · TAX_DISEASE_ANAPHYLAXIS

    Open source ↗
  19. BeOne Medicines Successfully Completes Negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for TEVIMBRA® in first-line Recurrent or Metastatic Nasopharyngeal Carcinoma

    Recorded role: co mention · TAX_DISEASE_NECK_CANCER

    Open source ↗

Signals to inspect

Anomalies

Latest 2 in the selected window (up to 10). Detector output, not verified conclusions.

medium · volume spike

Volume spike: 4 events in window (4.0x baseline of 1.0 expected)

high · volume spike

Volume spike: 5 events in window (5.0x baseline of 1.0 expected)

Narrative context

Unresolved threads

Latest 20 at most, across all dates. Stored narratives require human review.

No unresolved threads recorded.

Stored connections

Relationships

Up to 50 records ordered by evidence count, across all dates. Co-mentions indicate association in source material, not affiliation or coordination.

Ask this desk

Desk analyst

Read-only questions about Liza Helies's stored record. Answers cite only records retrieved for that turn; a citation chip opens the existing inspection view. Absence of matches is not evidence of inactivity.

Operator sign-in is required. Sign in

Identity is the existing actor registry record. Entity resolution and source coverage may be incomplete.